

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Body Mass Index (kg/m2)				
Baseline				
N	13			13
Mean (SD)	27.320 ( 3.5843)			27.320 ( 3.5843)
Median	26.060			26.060
Min, Max	22.530, 34.290			22.530, 34.290
Week 1				
N	13			13
Mean (SD)	27.305 ( 3.6008)			27.305 ( 3.6008)
Median	26.280			26.280
Min, Max	22.530, 34.290			22.530, 34.290
Change from Baseline to Week 1				
N	13			13
Mean (SD)	-0.015 ( 0.3474)			-0.015 ( 0.3474)
Median	0.000			0.000
Min, Max	-0.680, 0.610			-0.680, 0.610
Week 2				
N	13			13
Mean (SD)	27.205 ( 3.5373)			27.205 ( 3.5373)
Median	26.280			26.280
Min, Max	22.210, 33.960			22.210, 33.960

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	-0.115 ( 0.4374)			-0.115 ( 0.4374)
Median	0.000			0.000
Min, Max	-1.020, 0.370			-1.020, 0.370
Week 4				
N	1	12		13
Mean (SD)	31.940 ( )	26.647 ( 3.2656)		27.054 ( 3.4541)
Median	31.940	25.960		26.280
Min, Max	31.940, 31.940	21.830, 33.960		21.830, 33.960
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	-1.020 ( )	-0.203 ( 0.5792)		-0.266 ( 0.5990)
Median	-1.020	-0.155		-0.310
Min, Max	-1.020, -1.020	-1.130, 0.370		-1.130, 0.370
Week 6				
N	2	4	7	13
Mean (SD)	26.445 ( 7.0640)	27.333 ( 2.9918)	26.189 ( 2.4218)	26.580 ( 3.1000)
Median	26.445	26.780	25.680	25.880
Min, Max	21.450, 31.440	24.420, 31.350	22.840, 29.980	21.450, 31.440
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	-1.515 ( 0.0071)	-1.040 ( 1.3911)	-0.347 ( 0.9139)	-0.740 ( 1.0590)
Median	-1.515	-0.610	0.000	-0.300
Min, Max	-1.520, -1.510	-2.940, 0.000	-1.690, 0.750	-2.940, 0.750
Week 8				
N	2	2	9	13
Mean (SD)	26.635 ( 6.7953)	27.580 ( 5.3316)	26.138 ( 1.9199)	26.436 ( 2.9943)
Median	26.635	27.580	25.980	25.980
Min, Max	21.830, 31.440	23.810, 31.350	22.840, 28.410	21.830, 31.440
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	-1.325 ( 0.2758)	-2.385 ( 0.7849)	-0.452 ( 0.8805)	-0.884 ( 1.0593)
Median	-1.325	-2.385	0.000	-1.130
Min, Max	-1.520, -1.130	-2.940, -1.830	-1.690, 0.370	-2.940, 0.370
Week 12				
N	3	2	8	13
Mean (SD)	24.960 ( 4.9250)	27.580 ( 5.3316)	25.856 ( 1.4971)	25.915 ( 2.9002)
Median	22.840	27.580	26.300	26.230
Min, Max	21.450, 30.590	23.810, 31.350	23.720, 27.680	21.450, 31.350
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	-1.190 ( 1.3684)	-2.385 ( 0.7849)	-1.241 ( 1.7661)	-1.405 ( 1.5402)
Median	-1.510	-2.385	-0.790	-1.580
Min, Max	-2.370, 0.310	-2.940, -1.830	-3.750, 0.750	-3.750, 0.750
Week 16				
N	3	3	7	13
Mean (SD)	24.353 ( 3.8876)	27.200 ( 3.8270)	25.677 ( 1.2918)	25.723 ( 2.6096)
Median	22.840	26.440	25.720	25.720
Min, Max	21.450, 28.770	23.810, 31.350	23.720, 27.360	21.450, 31.350
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	-1.797 ( 2.2637)	-2.003 ( 0.8632)	-1.337 ( 2.1202)	-1.597 ( 1.8211)
Median	-1.510	-1.830	-1.580	-1.580
Min, Max	-4.190, 0.310	-2.940, -1.240	-4.260, 1.500	-4.260, 1.500
Week 20				
N	4	3	6	13
Mean (SD)	24.270 ( 3.1936)	27.300 ( 3.6958)	25.550 ( 1.8722)	25.560 ( 2.7565)
Median	23.415	26.440	26.030	25.590
Min, Max	21.450, 28.800	24.110, 31.350	22.050, 27.360	21.450, 31.350
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-2.838 ( 2.7902)	-1.903 ( 0.9094)	-0.970 ( 2.2000)	-1.760 ( 2.1920)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-2.835	-1.530	-0.315	-1.510
Min, Max	-5.990, 0.310	-2.940, -1.240	-4.010, 1.500	-5.990, 1.500
Week 24				
N	4	3	6	13
Mean (SD)	24.263 ( 3.0306)	27.190 ( 3.5155)	25.438 ( 2.4080)	25.481 ( 2.8281)
Median	23.570	26.440	26.360	26.350
Min, Max	21.450, 28.460	24.110, 31.020	20.720, 27.360	20.720, 31.020
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-2.845 ( 2.7394)	-2.013 ( 1.0979)	-1.082 ( 2.7851)	-1.839 ( 2.4374)
Median	-3.005	-1.530	-0.315	-1.510
Min, Max	-5.680, 0.310	-3.270, -1.240	-5.340, 2.260	-5.680, 2.260
Week 28				
N	4	3	6	13
Mean (SD)	24.788 ( 3.0327)	27.623 ( 3.1788)	25.997 ( 1.5058)	26.000 ( 2.4652)
Median	24.200	27.130	26.375	25.880
Min, Max	22.020, 28.730	24.720, 31.020	23.260, 27.360	22.020, 31.020
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-2.320 ( 2.3720)	-1.580 ( 1.4752)	-0.523 ( 1.8880)	-1.320 ( 1.9804)
Median	-2.585	-0.920	0.000	-0.920

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-4.420, 0.310	-3.270, -0.550	-2.880, 1.500	-4.420, 1.500
Week 32				
N	3	3	6	12
Mean (SD)	24.710 ( 3.6356)	27.713 ( 3.1617)	26.042 ( 1.3337)	26.127 ( 2.5034)
Median	22.840	27.400	26.150	26.150
Min, Max	22.390, 28.900	24.720, 31.020	23.760, 27.430	22.390, 31.020
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-1.440 ( 2.3113)	-1.490 ( 1.5744)	-0.478 ( 2.1756)	-0.972 ( 1.9594)
Median	-0.570	-0.920	0.350	-0.425
Min, Max	-4.060, 0.310	-3.270, -0.280	-3.960, 1.500	-4.060, 1.500
Week 36				
N	3	3	6	12
Mean (SD)	24.877 ( 3.4959)	28.050 ( 3.1251)	25.988 ( 1.2269)	26.226 ( 2.4732)
Median	23.150	28.340	26.180	26.180
Min, Max	22.580, 28.900	24.790, 31.020	23.790, 27.170	22.580, 31.020
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	-1.273 ( 2.4646)	-1.153 ( 1.9825)	-0.532 ( 2.0114)	-0.873 ( 1.9459)
Median	-0.380	-0.850	-0.010	-0.360
Min, Max	-4.060, 0.620	-3.270, 0.660	-3.590, 1.500	-4.060, 1.500

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	25.365 ( 3.0169)	28.620 ( 3.2622)	26.068 ( 1.1963)	26.441 ( 2.5075)
Median	24.990	28.370	26.270	26.510
Min, Max	22.580, 28.900	25.490, 32.000	23.990, 27.360	22.580, 32.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-1.743 ( 2.2203)	-0.583 ( 1.5365)	-0.452 ( 2.0223)	-0.879 ( 1.9214)
Median	-1.765	-0.150	0.315	-0.150
Min, Max	-4.060, 0.620	-2.290, 0.690	-3.720, 1.500	-4.060, 1.500
Week 44				
N	4	3	6	13
Mean (SD)	25.530 ( 2.7594)	28.493 ( 3.2034)	26.190 ( 0.9836)	26.518 ( 2.3177)
Median	25.085	29.100	26.270	26.510
Min, Max	23.150, 28.800	25.030, 31.350	24.660, 27.360	23.150, 31.350
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	-1.578 ( 2.4360)	-0.710 ( 2.1817)	-0.330 ( 1.9397)	-0.802 ( 2.0392)
Median	-1.385	-0.610	0.315	0.000
Min, Max	-4.160, 0.620	-2.940, 1.420	-3.720, 1.500	-4.160, 1.500
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	25.795 ( 2.6935)	28.560 ( 3.1849)	26.218 ( 0.9806)	26.628 ( 2.2701)
Median	25.455	29.240	26.355	26.510
Min, Max	23.340, 28.930	25.090, 31.350	24.660, 27.360	23.340, 31.350
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	-1.313 ( 2.5231)	-0.643 ( 2.2515)	-0.302 ( 1.8806)	-0.692 ( 2.0286)
Median	-1.230	-0.550	0.315	0.000
Min, Max	-4.030, 1.240	-2.940, 1.560	-3.550, 1.500	-4.030, 1.560

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Diastolic Blood Pressure (mmHg)				
Baseline				
N	13			13
Mean (SD)	73.077 ( 10.3155)			73.077 ( 10.3155)
Median	80.000			80.000
Min, Max	60.000, 90.000			60.000, 90.000
Week 1				
N	13			13
Mean (SD)	72.308 ( 10.1274)			72.308 ( 10.1274)
Median	70.000			70.000
Min, Max	60.000, 90.000			60.000, 90.000
Change from Baseline to Week 1				
N	13			13
Mean (SD)	-0.769 ( 10.3775)			-0.769 ( 10.3775)
Median	0.000			0.000
Min, Max	-20.000, 20.000			-20.000, 20.000
Week 2				
N	13			13
Mean (SD)	68.077 ( 9.0228)			68.077 ( 9.0228)
Median	70.000			70.000
Min, Max	50.000, 80.000			50.000, 80.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	-5.000 ( 11.5470)			-5.000 ( 11.5470)
Median	-10.000			-10.000
Min, Max	-20.000, 10.000			-20.000, 10.000
Week 4				
N	1	12		13
Mean (SD)	70.000 ( )	71.667 ( 9.6138)		71.538 ( 9.2161)
Median	70.000	70.000		70.000
Min, Max	70.000, 70.000	55.000, 85.000		55.000, 85.000
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	0.000 ( )	-1.667 ( 10.9406)		-1.538 ( 10.4850)
Median	0.000	-2.500		0.000
Min, Max	0.000, 0.000	-20.000, 20.000		-20.000, 20.000
Week 6				
N	2	4	7	13
Mean (SD)	65.000 ( 21.2132)	67.500 ( 5.0000)	68.571 ( 6.9007)	67.692 ( 8.3205)
Median	65.000	70.000	70.000	70.000
Min, Max	50.000, 80.000	60.000, 70.000	60.000, 80.000	50.000, 80.000
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	0.000 ( 14.1421)	-10.000 ( 8.1650)	-4.286 ( 12.7242)	-5.385 ( 11.2660)
Median	0.000	-10.000	0.000	-10.000
Min, Max	-10.000, 10.000	-20.000, 0.000	-20.000, 10.000	-20.000, 10.000
Week 8				
N	2	2	9	13
Mean (SD)	75.000 ( 21.2132)	75.000 ( 21.2132)	71.667 ( 8.6603)	72.692 ( 11.2944)
Median	75.000	75.000	70.000	70.000
Min, Max	60.000, 90.000	60.000, 90.000	60.000, 85.000	60.000, 90.000
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	10.000 ( 14.1421)	-5.000 ( 21.2132)	-1.667 ( 15.0000)	-0.385 ( 15.0640)
Median	10.000	-5.000	0.000	0.000
Min, Max	0.000, 20.000	-20.000, 10.000	-30.000, 20.000	-30.000, 20.000
Week 12				
N	3	2	8	13
Mean (SD)	63.333 ( 5.7735)	70.000 ( 0.0000)	67.500 ( 10.3510)	66.923 ( 8.5485)
Median	60.000	70.000	70.000	70.000
Min, Max	60.000, 70.000	70.000, 70.000	50.000, 80.000	50.000, 80.000
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	-6.667 ( 11.5470)	-10.000 ( 0.0000)	-5.000 ( 10.6904)	-6.154 ( 9.6077)
Median	0.000	-10.000	0.000	0.000
Min, Max	-20.000, 0.000	-10.000, -10.000	-20.000, 10.000	-20.000, 10.000
Week 16				
N	3	3	7	13
Mean (SD)	70.000 ( 10.0000)	66.667 ( 5.7735)	68.571 ( 10.6904)	68.462 ( 8.9872)
Median	70.000	70.000	60.000	70.000
Min, Max	60.000, 80.000	60.000, 70.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	0.000 ( 10.0000)	-10.000 ( 0.0000)	-4.286 ( 16.1835)	-4.615 ( 12.6592)
Median	0.000	-10.000	0.000	0.000
Min, Max	-10.000, 10.000	-10.000, -10.000	-30.000, 20.000	-30.000, 20.000
Week 20				
N	4	3	6	13
Mean (SD)	65.000 ( 5.7735)	66.667 ( 5.7735)	63.333 ( 10.3280)	64.615 ( 7.7625)
Median	65.000	70.000	60.000	60.000
Min, Max	60.000, 70.000	60.000, 70.000	50.000, 80.000	50.000, 80.000
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-10.000 ( 11.5470)	-10.000 ( 10.0000)	-6.667 ( 8.1650)	-8.462 ( 8.9872)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-10.000	-10.000	-5.000	-10.000
Min, Max	-20.000, 0.000	-20.000, 0.000	-20.000, 0.000	-20.000, 0.000
Week 24				
N	4	3	6	13
Mean (SD)	62.500 ( 5.0000)	73.333 ( 11.5470)	73.333 ( 8.1650)	70.000 ( 9.1287)
Median	60.000	80.000	75.000	70.000
Min, Max	60.000, 70.000	60.000, 80.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-12.500 ( 12.5831)	-3.333 ( 15.2753)	3.333 ( 10.3280)	-3.077 ( 13.1559)
Median	-10.000	0.000	0.000	0.000
Min, Max	-30.000, 0.000	-20.000, 10.000	-10.000, 20.000	-30.000, 20.000
Week 28				
N	4	3	6	13
Mean (SD)	67.500 ( 5.0000)	73.333 ( 11.5470)	75.000 ( 8.3666)	72.308 ( 8.3205)
Median	70.000	80.000	80.000	70.000
Min, Max	60.000, 70.000	60.000, 80.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-7.500 ( 9.5743)	-3.333 ( 5.7735)	5.000 ( 8.3666)	-0.769 ( 9.5407)
Median	-5.000	0.000	0.000	0.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-20.000, 0.000	-10.000, 0.000	0.000, 20.000	-20.000, 20.000
Week 32				
N	3	3	6	12
Mean (SD)	66.667 ( 15.2753)	73.333 ( 11.5470)	73.333 ( 5.1640)	71.667 ( 9.3744)
Median	70.000	80.000	70.000	70.000
Min, Max	50.000, 80.000	60.000, 80.000	70.000, 80.000	50.000, 80.000
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-3.333 ( 11.5470)	-3.333 ( 5.7735)	3.333 ( 8.1650)	0.000 ( 8.5280)
Median	-10.000	0.000	5.000	0.000
Min, Max	-10.000, 10.000	-10.000, 0.000	-10.000, 10.000	-10.000, 10.000
Week 36				
N	3	3	6	12
Mean (SD)	70.000 ( 10.0000)	63.333 ( 5.7735)	68.333 ( 7.5277)	67.500 ( 7.5378)
Median	70.000	60.000	70.000	70.000
Min, Max	60.000, 80.000	60.000, 70.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	0.000 ( 10.0000)	-13.333 ( 5.7735)	-1.667 ( 11.6905)	-4.167 ( 10.8362)
Median	0.000	-10.000	-5.000	-10.000
Min, Max	-10.000, 10.000	-20.000, -10.000	-10.000, 20.000	-20.000, 20.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	72.500 ( 9.5743)	70.000 ( 10.0000)	66.667 ( 5.1640)	69.231 ( 7.5955)
Median	75.000	70.000	70.000	70.000
Min, Max	60.000, 80.000	60.000, 80.000	60.000, 70.000	60.000, 80.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-2.500 ( 12.5831)	-6.667 ( 5.7735)	-3.333 ( 12.1106)	-3.846 ( 10.4391)
Median	0.000	-10.000	-5.000	0.000
Min, Max	-20.000, 10.000	-10.000, 0.000	-20.000, 10.000	-20.000, 10.000
Week 44				
N	4	3	6	13
Mean (SD)	65.000 ( 5.7735)	66.667 ( 5.7735)	71.667 ( 7.5277)	68.462 ( 6.8874)
Median	65.000	70.000	70.000	70.000
Min, Max	60.000, 70.000	60.000, 70.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	-10.000 ( 11.5470)	-10.000 ( 10.0000)	1.667 ( 7.5277)	-4.615 ( 10.5003)
Median	-10.000	-10.000	0.000	0.000
Min, Max	-20.000, 0.000	-20.000, 0.000	-10.000, 10.000	-20.000, 10.000
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	72.500 ( 9.5743)	70.000 ( 10.0000)	73.333 ( 8.1650)	72.308 ( 8.3205)
Median	75.000	70.000	75.000	70.000
Min, Max	60.000, 80.000	60.000, 80.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	-2.500 ( 9.5743)	-6.667 ( 11.5470)	3.333 ( 10.3280)	-0.769 ( 10.3775)
Median	-5.000	0.000	0.000	0.000
Min, Max	-10.000, 10.000	-20.000, 0.000	-10.000, 20.000	-20.000, 20.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Pulse Rate (beats/min)				
Baseline				
N	13			13
Mean (SD)	67.385 ( 6.2920)			67.385 ( 6.2920)
Median	68.000			68.000
Min, Max	60.000, 84.000			60.000, 84.000
Week 1				
N	13			13
Mean (SD)	65.538 ( 5.0434)			65.538 ( 5.0434)
Median	64.000			64.000
Min, Max	60.000, 76.000			60.000, 76.000
Change from Baseline to Week 1				
N	13			13
Mean (SD)	-1.846 ( 8.2648)			-1.846 ( 8.2648)
Median	0.000			0.000
Min, Max	-20.000, 12.000			-20.000, 12.000
Week 2				
N	13			13
Mean (SD)	67.538 ( 7.4902)			67.538 ( 7.4902)
Median	68.000			68.000
Min, Max	54.000, 80.000			54.000, 80.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	0.154 ( 6.9504)			0.154 ( 6.9504)
Median	0.000			0.000
Min, Max	-14.000, 12.000			-14.000, 12.000
Week 4				
N	1	12		13
Mean (SD)	64.000 ( )	67.500 ( 6.9348)		67.231 ( 6.7101)
Median	64.000	66.000		64.000
Min, Max	64.000, 64.000	58.000, 84.000		58.000, 84.000
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	0.000 ( )	-0.167 ( 7.5538)		-0.154 ( 7.2324)
Median	0.000	-2.000		0.000
Min, Max	0.000, 0.000	-14.000, 12.000		-14.000, 12.000
Week 6				
N	2	4	7	13
Mean (SD)	60.000 ( 5.6569)	66.000 ( 5.1640)	69.714 ( 6.4734)	67.077 ( 6.5633)
Median	60.000	66.000	68.000	64.000
Min, Max	56.000, 64.000	60.000, 72.000	64.000, 80.000	56.000, 80.000
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	-6.000 ( 8.4853)	1.000 ( 2.0000)	0.571 ( 7.0912)	-0.308 ( 6.2100)
Median	-6.000	0.000	0.000	0.000
Min, Max	-12.000, 0.000	0.000, 4.000	-8.000, 12.000	-12.000, 12.000
Week 8				
N	2	2	9	13
Mean (SD)	61.000 ( 7.0711)	62.000 ( 2.8284)	68.222 ( 8.0898)	66.154 ( 7.6795)
Median	61.000	62.000	64.000	64.000
Min, Max	56.000, 66.000	60.000, 64.000	60.000, 80.000	56.000, 80.000
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	-5.000 ( 9.8995)	0.000 ( 0.0000)	-0.667 ( 8.4261)	-1.231 ( 7.6393)
Median	-5.000	0.000	-4.000	-2.000
Min, Max	-12.000, 2.000	0.000, 0.000	-12.000, 18.000	-12.000, 18.000
Week 12				
N	3	2	8	13
Mean (SD)	61.333 ( 2.3094)	60.000 ( 0.0000)	68.500 ( 14.4123)	65.538 ( 11.7233)
Median	60.000	60.000	62.000	60.000
Min, Max	60.000, 64.000	60.000, 60.000	60.000, 100.000	60.000, 100.000
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	-5.333 ( 2.3094)	-2.000 ( 2.8284)	-0.500 ( 10.7836)	-1.846 ( 8.5814)
Median	-4.000	-2.000	-4.000	-4.000
Min, Max	-8.000, -4.000	-4.000, 0.000	-12.000, 16.000	-12.000, 16.000
Week 16				
N	3	3	7	13
Mean (SD)	61.333 ( 2.3094)	62.667 ( 2.3094)	66.857 ( 7.5593)	64.615 ( 6.0764)
Median	60.000	64.000	64.000	64.000
Min, Max	60.000, 64.000	60.000, 64.000	64.000, 84.000	60.000, 84.000
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	-5.333 ( 2.3094)	-1.333 ( 4.6188)	-2.286 ( 4.5356)	-2.769 ( 4.1262)
Median	-4.000	-4.000	0.000	-4.000
Min, Max	-8.000, -4.000	-4.000, 4.000	-8.000, 4.000	-8.000, 4.000
Week 20				
N	4	3	6	13
Mean (SD)	57.750 ( 6.4485)	60.667 ( 5.0332)	66.000 ( 7.0427)	62.231 ( 7.0493)
Median	58.500	60.000	64.000	64.000
Min, Max	50.000, 64.000	56.000, 66.000	60.000, 80.000	50.000, 80.000
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-10.250 ( 9.4648)	-3.333 ( 1.1547)	-2.667 ( 3.2660)	-5.154 ( 6.2961)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-9.500	-4.000	-2.000	-4.000
Min, Max	-22.000, 0.000	-4.000, -2.000	-8.000, 0.000	-22.000, 0.000
Week 24				
N	4	3	6	13
Mean (SD)	61.000 ( 2.0000)	63.000 ( 2.6458)	71.000 ( 8.9889)	66.077 ( 7.6753)
Median	60.000	64.000	73.500	64.000
Min, Max	60.000, 64.000	60.000, 65.000	60.000, 80.000	60.000, 80.000
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-7.000 ( 5.0332)	-1.000 ( 5.1962)	2.333 ( 10.5198)	-1.308 ( 8.6254)
Median	-8.000	-4.000	-2.000	-4.000
Min, Max	-12.000, 0.000	-4.000, 5.000	-8.000, 16.000	-12.000, 16.000
Week 28				
N	4	3	6	13
Mean (SD)	61.000 ( 2.0000)	63.333 ( 3.0551)	72.000 ( 11.2428)	66.615 ( 9.1062)
Median	60.000	64.000	69.000	64.000
Min, Max	60.000, 64.000	60.000, 66.000	60.000, 90.000	60.000, 90.000
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-7.000 ( 3.8297)	-0.667 ( 6.4291)	3.333 ( 9.6885)	-0.769 ( 8.4277)
Median	-6.000	2.000	3.000	-4.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-12.000, -4.000	-8.000, 4.000	-8.000, 16.000	-12.000, 16.000
Week 32				
N	3	3	6	12
Mean (SD)	62.667 ( 4.6188)	61.333 ( 2.3094)	68.000 ( 8.7636)	65.000 ( 7.0582)
Median	60.000	60.000	64.000	64.000
Min, Max	60.000, 68.000	60.000, 64.000	60.000, 84.000	60.000, 84.000
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-4.000 ( 4.0000)	-2.667 ( 6.1101)	-0.667 ( 6.8896)	-2.000 ( 5.7840)
Median	-4.000	-4.000	0.000	-2.000
Min, Max	-8.000, 0.000	-8.000, 4.000	-12.000, 8.000	-12.000, 8.000
Week 36				
N	3	3	6	12
Mean (SD)	64.000 ( 4.0000)	60.000 ( 4.0000)	67.000 ( 7.9750)	64.500 ( 6.6127)
Median	64.000	60.000	64.000	64.000
Min, Max	60.000, 68.000	56.000, 64.000	60.000, 78.000	56.000, 78.000
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	-2.667 ( 6.1101)	-4.000 ( 0.0000)	-1.667 ( 8.9815)	-2.500 ( 6.6674)
Median	-4.000	-4.000	-6.000	-4.000
Min, Max	-8.000, 4.000	-4.000, -4.000	-8.000, 14.000	-8.000, 14.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	63.500 ( 2.5166)	65.333 ( 2.3094)	68.000 ( 10.1193)	66.000 ( 7.0238)
Median	64.000	64.000	64.000	64.000
Min, Max	60.000, 66.000	64.000, 68.000	60.000, 88.000	60.000, 88.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-4.500 ( 4.1231)	1.333 ( 2.3094)	-0.667 ( 5.8878)	-1.385 ( 4.9923)
Median	-5.000	0.000	0.000	0.000
Min, Max	-8.000, 0.000	0.000, 4.000	-12.000, 4.000	-12.000, 4.000
Week 44				
N	4	3	6	13
Mean (SD)	62.000 ( 2.3094)	62.667 ( 4.6188)	66.667 ( 5.3166)	64.308 ( 4.6795)
Median	62.000	60.000	66.000	64.000
Min, Max	60.000, 64.000	60.000, 68.000	60.000, 76.000	60.000, 76.000
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	-6.000 ( 2.3094)	-1.333 ( 2.3094)	-2.000 ( 5.0596)	-3.077 ( 4.1324)
Median	-6.000	0.000	-3.000	-4.000
Min, Max	-8.000, -4.000	-4.000, 0.000	-8.000, 4.000	-8.000, 4.000
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	62.000 ( 2.3094)	61.333 ( 2.3094)	67.333 ( 2.7325)	64.308 ( 3.7279)
Median	62.000	60.000	67.000	64.000
Min, Max	60.000, 64.000	60.000, 64.000	64.000, 72.000	60.000, 72.000
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	-6.000 ( 4.0000)	-2.667 ( 2.3094)	-1.333 ( 9.7707)	-3.077 ( 7.0055)
Median	-4.000	-4.000	0.000	-4.000
Min, Max	-12.000, -4.000	-4.000, 0.000	-18.000, 12.000	-18.000, 12.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Respiratory Rate (breaths/min)				
Baseline				
N	13			13
Mean (SD)	12.615 ( 0.7679)			12.615 ( 0.7679)
Median	12.000			12.000
Min, Max	12.000, 14.000			12.000, 14.000
Week 1				
N	13			13
Mean (SD)	12.615 ( 0.6504)			12.615 ( 0.6504)
Median	13.000			13.000
Min, Max	12.000, 14.000			12.000, 14.000
Change from Baseline to Week 1				
N	13			13
Mean (SD)	0.000 ( 0.9129)			0.000 ( 0.9129)
Median	0.000			0.000
Min, Max	-1.000, 2.000			-1.000, 2.000
Week 2				
N	13			13
Mean (SD)	12.538 ( 1.0500)			12.538 ( 1.0500)
Median	12.000			12.000
Min, Max	11.000, 14.000			11.000, 14.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	-0.077 ( 1.1152)			-0.077 ( 1.1152)
Median	0.000			0.000
Min, Max	-2.000, 2.000			-2.000, 2.000
Week 4				
N	1	12		13
Mean (SD)	13.000 ( )	12.167 ( 1.0299)		12.231 ( 1.0127)
Median	13.000	12.500		13.000
Min, Max	13.000, 13.000	10.000, 13.000		10.000, 13.000
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	-1.000 ( )	-0.333 ( 1.3707)		-0.385 ( 1.3253)
Median	-1.000	0.000		0.000
Min, Max	-1.000, -1.000	-3.000, 1.000		-3.000, 1.000
Week 6				
N	2	4	7	13
Mean (SD)	12.500 ( 0.7071)	12.750 ( 0.5000)	12.714 ( 0.7559)	12.692 ( 0.6304)
Median	12.500	13.000	13.000	13.000
Min, Max	12.000, 13.000	12.000, 13.000	12.000, 14.000	12.000, 14.000
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	-1.000 ( 0.0000)	0.000 ( 1.1547)	0.429 ( 0.9759)	0.077 ( 1.0377)
Median	-1.000	0.000	0.000	0.000
Min, Max	-1.000, -1.000	-1.000, 1.000	-1.000, 2.000	-1.000, 2.000
Week 8				
N	2	2	9	13
Mean (SD)	12.000 ( 0.0000)	12.000 ( 0.0000)	12.222 ( 1.2019)	12.154 ( 0.9871)
Median	12.000	12.000	12.000	12.000
Min, Max	12.000, 12.000	12.000, 12.000	10.000, 14.000	10.000, 14.000
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	-1.500 ( 0.7071)	-0.500 ( 0.7071)	-0.222 ( 1.5635)	-0.462 ( 1.3914)
Median	-1.500	-0.500	0.000	0.000
Min, Max	-2.000, -1.000	-1.000, 0.000	-3.000, 2.000	-3.000, 2.000
Week 12				
N	3	2	8	13
Mean (SD)	12.667 ( 0.5774)	11.500 ( 0.7071)	12.000 ( 0.5345)	12.077 ( 0.6405)
Median	13.000	11.500	12.000	12.000
Min, Max	12.000, 13.000	11.000, 12.000	11.000, 13.000	11.000, 13.000
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	-0.333 ( 1.1547)	-1.000 ( 0.0000)	-0.500 ( 0.9258)	-0.538 ( 0.8771)
Median	-1.000	-1.000	-0.500	-1.000
Min, Max	-1.000, 1.000	-1.000, -1.000	-2.000, 1.000	-2.000, 1.000
Week 16				
N	3	3	7	13
Mean (SD)	12.333 ( 0.5774)	12.667 ( 0.5774)	12.429 ( 0.5345)	12.462 ( 0.5189)
Median	12.000	13.000	12.000	12.000
Min, Max	12.000, 13.000	12.000, 13.000	12.000, 13.000	12.000, 13.000
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	-0.667 ( 1.1547)	-0.333 ( 0.5774)	0.143 ( 0.3780)	-0.154 ( 0.6887)
Median	0.000	0.000	0.000	0.000
Min, Max	-2.000, 0.000	-1.000, 0.000	0.000, 1.000	-2.000, 1.000
Week 20				
N	4	3	6	13
Mean (SD)	12.750 ( 0.9574)	12.667 ( 1.1547)	12.833 ( 0.7528)	12.769 ( 0.8321)
Median	12.500	12.000	13.000	13.000
Min, Max	12.000, 14.000	12.000, 14.000	12.000, 14.000	12.000, 14.000
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-0.250 ( 0.9574)	-0.333 ( 0.5774)	0.667 ( 1.0328)	0.154 ( 0.9871)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-0.500	0.000	1.000	0.000
Min, Max	-1.000, 1.000	-1.000, 0.000	-1.000, 2.000	-1.000, 2.000
Week 24				
N	4	3	6	13
Mean (SD)	12.750 ( 0.5000)	14.000 ( 1.0000)	12.333 ( 0.5164)	12.846 ( 0.8987)
Median	13.000	14.000	12.000	13.000
Min, Max	12.000, 13.000	13.000, 15.000	12.000, 13.000	12.000, 15.000
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-0.250 ( 0.9574)	1.000 ( 0.0000)	0.167 ( 0.7528)	0.231 ( 0.8321)
Median	-0.500	1.000	0.000	0.000
Min, Max	-1.000, 1.000	1.000, 1.000	-1.000, 1.000	-1.000, 1.000
Week 28				
N	4	3	6	13
Mean (SD)	12.500 ( 0.5774)	13.667 ( 1.1547)	13.000 ( 0.6325)	13.000 ( 0.8165)
Median	12.500	13.000	13.000	13.000
Min, Max	12.000, 13.000	13.000, 15.000	12.000, 14.000	12.000, 15.000
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-0.500 ( 1.0000)	0.667 ( 2.0817)	0.833 ( 0.7528)	0.385 ( 1.2609)
Median	0.000	0.000	1.000	0.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-2.000, 0.000	-1.000, 3.000	0.000, 2.000	-2.000, 3.000
Week 32				
N	3	3	6	12
Mean (SD)	12.667 ( 0.5774)	13.000 ( 1.0000)	12.833 ( 0.4082)	12.833 ( 0.5774)
Median	13.000	13.000	13.000	13.000
Min, Max	12.000, 13.000	12.000, 14.000	12.000, 13.000	12.000, 14.000
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-0.333 ( 1.1547)	0.000 ( 1.7321)	0.667 ( 0.5164)	0.250 ( 1.0553)
Median	-1.000	-1.000	1.000	0.500
Min, Max	-1.000, 1.000	-1.000, 2.000	0.000, 1.000	-1.000, 2.000
Week 36				
N	3	3	6	12
Mean (SD)	12.667 ( 0.5774)	12.667 ( 0.5774)	13.000 ( 0.0000)	12.833 ( 0.3892)
Median	13.000	13.000	13.000	13.000
Min, Max	12.000, 13.000	12.000, 13.000	13.000, 13.000	12.000, 13.000
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	-0.333 ( 0.5774)	-0.333 ( 1.1547)	0.833 ( 0.4082)	0.250 ( 0.8660)
Median	0.000	-1.000	1.000	0.500
Min, Max	-1.000, 0.000	-1.000, 1.000	0.000, 1.000	-1.000, 1.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	12.250 ( 0.5000)	13.000 ( 0.0000)	12.500 ( 0.5477)	12.538 ( 0.5189)
Median	12.000	13.000	12.500	13.000
Min, Max	12.000, 13.000	13.000, 13.000	12.000, 13.000	12.000, 13.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-0.750 ( 1.2583)	0.000 ( 1.0000)	0.333 ( 0.8165)	-0.077 ( 1.0377)
Median	-1.000	0.000	0.500	0.000
Min, Max	-2.000, 1.000	-1.000, 1.000	-1.000, 1.000	-2.000, 1.000
Week 44				
N	4	3	6	13
Mean (SD)	13.000 ( 0.0000)	12.667 ( 0.5774)	13.667 ( 1.0328)	13.231 ( 0.8321)
Median	13.000	13.000	13.000	13.000
Min, Max	13.000, 13.000	12.000, 13.000	13.000, 15.000	12.000, 15.000
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	0.000 ( 0.8165)	-0.333 ( 0.5774)	1.500 ( 1.2247)	0.615 ( 1.2609)
Median	0.000	0.000	1.000	0.000
Min, Max	-1.000, 1.000	-1.000, 0.000	0.000, 3.000	-1.000, 3.000
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	12.750 ( 0.5000)	13.000 ( 0.0000)	12.833 ( 0.7528)	12.846 ( 0.5547)
Median	13.000	13.000	13.000	13.000
Min, Max	12.000, 13.000	13.000, 13.000	12.000, 14.000	12.000, 14.000
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	-0.250 ( 0.5000)	0.000 ( 1.0000)	0.667 ( 0.5164)	0.231 ( 0.7250)
Median	0.000	0.000	1.000	0.000
Min, Max	-1.000, 0.000	-1.000, 1.000	0.000, 1.000	-1.000, 1.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Systolic Blood Pressure (mmHg)				
Baseline				
N	13			13
Mean (SD)	123.077 ( 19.3152)			123.077 ( 19.3152)
Median	130.000			130.000
Min, Max	100.000, 160.000			100.000, 160.000
Week 1				
N	13			13
Mean (SD)	116.538 ( 14.6322)			116.538 ( 14.6322)
Median	120.000			120.000
Min, Max	90.000, 140.000			90.000, 140.000
Change from Baseline to Week 1				
N	13			13
Mean (SD)	-6.538 ( 13.4450)			-6.538 ( 13.4450)
Median	-10.000			-10.000
Min, Max	-30.000, 10.000			-30.000, 10.000
Week 2				
N	13			13
Mean (SD)	119.615 ( 20.0480)			119.615 ( 20.0480)
Median	120.000			120.000
Min, Max	90.000, 150.000			90.000, 150.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	-3.462 ( 20.9548)			-3.462 ( 20.9548)
Median	-5.000			-5.000
Min, Max	-40.000, 30.000			-40.000, 30.000
Week 4				
N	1	12		13
Mean (SD)	110.000 ( )	117.500 ( 12.1543)		116.923 ( 11.8213)
Median	110.000	120.000		120.000
Min, Max	110.000, 110.000	100.000, 140.000		100.000, 140.000
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	0.000 ( )	-6.667 ( 15.5700)		-6.154 ( 15.0214)
Median	0.000	-5.000		0.000
Min, Max	0.000, 0.000	-30.000, 10.000		-30.000, 10.000
Week 6				
N	2	4	7	13
Mean (SD)	110.000 ( 14.1421)	112.500 ( 5.0000)	124.286 ( 13.9728)	118.462 ( 12.8103)
Median	110.000	110.000	120.000	120.000
Min, Max	100.000, 120.000	110.000, 120.000	110.000, 150.000	100.000, 150.000
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	5.000 ( 7.0711)	-15.000 ( 12.9099)	-1.429 ( 16.7616)	-4.615 ( 15.6074)
Median	5.000	-15.000	0.000	0.000
Min, Max	0.000, 10.000	-30.000, 0.000	-30.000, 20.000	-30.000, 20.000
Week 8				
N	2	2	9	13
Mean (SD)	112.500 ( 24.7487)	135.000 ( 21.2132)	112.778 ( 9.0523)	116.154 ( 14.5994)
Median	112.500	135.000	110.000	110.000
Min, Max	95.000, 130.000	120.000, 150.000	100.000, 130.000	95.000, 150.000
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	7.500 ( 17.6777)	5.000 ( 21.2132)	-12.778 ( 22.7913)	-6.923 ( 22.2241)
Median	7.500	5.000	-20.000	-5.000
Min, Max	-5.000, 20.000	-10.000, 20.000	-50.000, 20.000	-50.000, 20.000
Week 12				
N	3	2	8	13
Mean (SD)	116.667 ( 11.5470)	115.000 ( 7.0711)	115.000 ( 14.1421)	115.385 ( 11.9829)
Median	110.000	115.000	115.000	110.000
Min, Max	110.000, 130.000	110.000, 120.000	100.000, 130.000	100.000, 130.000
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	0.000 ( 26.4575)	-15.000 ( 7.0711)	-8.750 ( 20.3101)	-7.692 ( 19.6443)
Median	10.000	-15.000	-5.000	-10.000
Min, Max	-30.000, 20.000	-20.000, -10.000	-50.000, 20.000	-50.000, 20.000
Week 16				
N	3	3	7	13
Mean (SD)	115.000 ( 18.0278)	116.667 ( 5.7735)	115.714 ( 9.7590)	115.769 ( 10.3775)
Median	120.000	120.000	120.000	120.000
Min, Max	95.000, 130.000	110.000, 120.000	100.000, 130.000	95.000, 130.000
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	-1.667 ( 10.4083)	-6.667 ( 5.7735)	-10.000 ( 28.2843)	-7.308 ( 20.8782)
Median	-5.000	-10.000	-10.000	-10.000
Min, Max	-10.000, 10.000	-10.000, 0.000	-50.000, 20.000	-50.000, 20.000
Week 20				
N	4	3	6	13
Mean (SD)	107.500 ( 12.5831)	113.333 ( 11.5470)	113.333 ( 10.3280)	111.538 ( 10.6819)
Median	110.000	120.000	110.000	110.000
Min, Max	90.000, 120.000	100.000, 120.000	100.000, 130.000	90.000, 130.000
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-20.000 ( 25.8199)	-10.000 ( 20.0000)	-6.667 ( 15.0555)	-11.538 ( 19.0815)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-20.000	-10.000	0.000	-10.000
Min, Max	-50.000, 10.000	-30.000, 10.000	-30.000, 10.000	-50.000, 10.000
Week 24				
N	4	3	6	13
Mean (SD)	107.500 ( 5.0000)	118.333 ( 17.5594)	118.333 ( 14.7196)	115.000 ( 13.2288)
Median	110.000	120.000	125.000	110.000
Min, Max	100.000, 110.000	100.000, 135.000	100.000, 130.000	100.000, 135.000
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-20.000 ( 24.4949)	-5.000 ( 21.7945)	-1.667 ( 13.2916)	-8.077 ( 19.3152)
Median	-15.000	5.000	0.000	0.000
Min, Max	-50.000, 0.000	-30.000, 10.000	-20.000, 20.000	-50.000, 20.000
Week 28				
N	4	3	6	13
Mean (SD)	108.750 ( 10.3078)	113.333 ( 11.5470)	121.667 ( 9.8319)	115.769 ( 11.1516)
Median	110.000	120.000	125.000	120.000
Min, Max	95.000, 120.000	100.000, 120.000	110.000, 130.000	95.000, 130.000
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-18.750 ( 19.3111)	-10.000 ( 0.0000)	1.667 ( 14.7196)	-7.308 ( 16.4083)
Median	-17.500	-10.000	5.000	-10.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-40.000, 0.000	-10.000, -10.000	-20.000, 20.000	-40.000, 20.000
Week 32				
N	3	3	6	12
Mean (SD)	106.667 ( 15.2753)	116.667 ( 15.2753)	118.333 ( 13.2916)	115.000 ( 13.8170)
Median	110.000	120.000	120.000	120.000
Min, Max	90.000, 120.000	100.000, 130.000	100.000, 140.000	90.000, 140.000
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-10.000 ( 20.0000)	-6.667 ( 5.7735)	-1.667 ( 16.0208)	-5.000 ( 14.4600)
Median	-10.000	-10.000	0.000	-5.000
Min, Max	-30.000, 10.000	-10.000, 0.000	-20.000, 20.000	-30.000, 20.000
Week 36				
N	3	3	6	12
Mean (SD)	113.333 ( 20.8167)	110.000 ( 10.0000)	113.333 ( 12.1106)	112.500 ( 12.8806)
Median	120.000	110.000	115.000	115.000
Min, Max	90.000, 130.000	100.000, 120.000	100.000, 130.000	90.000, 130.000
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	-3.333 ( 20.8167)	-13.333 ( 5.7735)	-6.667 ( 13.6626)	-7.500 ( 13.5680)
Median	-10.000	-10.000	-5.000	-10.000
Min, Max	-20.000, 20.000	-20.000, -10.000	-30.000, 10.000	-30.000, 20.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	120.000 ( 18.2574)	113.333 ( 15.2753)	121.667 ( 14.7196)	119.231 ( 14.9786)
Median	120.000	110.000	125.000	120.000
Min, Max	100.000, 140.000	100.000, 130.000	100.000, 140.000	100.000, 140.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-7.500 ( 22.1736)	-10.000 ( 10.0000)	1.667 ( 20.4124)	-3.846 ( 18.5016)
Median	-10.000	-10.000	5.000	0.000
Min, Max	-30.000, 20.000	-20.000, 0.000	-30.000, 30.000	-30.000, 30.000
Week 44				
N	4	3	6	13
Mean (SD)	122.500 ( 20.6155)	113.333 ( 11.5470)	118.333 ( 11.6905)	118.462 ( 14.0512)
Median	120.000	120.000	120.000	120.000
Min, Max	100.000, 150.000	100.000, 120.000	100.000, 130.000	100.000, 150.000
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	-5.000 ( 12.9099)	-10.000 ( 0.0000)	-1.667 ( 16.0208)	-4.615 ( 12.6592)
Median	-5.000	-10.000	0.000	-10.000
Min, Max	-20.000, 10.000	-10.000, -10.000	-20.000, 20.000	-20.000, 20.000
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	130.000 ( 21.6025)	113.333 ( 15.2753)	121.667 ( 17.2240)	122.308 ( 17.8670)
Median	125.000	110.000	120.000	120.000
Min, Max	110.000, 160.000	100.000, 130.000	100.000, 150.000	100.000, 160.000
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	2.500 ( 17.0783)	-10.000 ( 17.3205)	1.667 ( 14.7196)	-0.769 ( 15.5250)
Median	5.000	0.000	5.000	0.000
Min, Max	-20.000, 20.000	-30.000, 0.000	-20.000, 20.000	-30.000, 20.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Temperature (C)				
Baseline				
N	13			13
Mean (SD)	36.238 ( 0.1895)			36.238 ( 0.1895)
Median	36.200			36.200
Min, Max	36.000, 36.500			36.000, 36.500
Week 1				
N	13			13
Mean (SD)	36.369 ( 0.4191)			36.369 ( 0.4191)
Median	36.200			36.200
Min, Max	36.000, 37.700			36.000, 37.700
Change from Baseline to Week 1				
N	13			13
Mean (SD)	0.131 ( 0.4608)			0.131 ( 0.4608)
Median	0.000			0.000
Min, Max	-0.300, 1.500			-0.300, 1.500
Week 2				
N	13			13
Mean (SD)	36.369 ( 0.2175)			36.369 ( 0.2175)
Median	36.300			36.300
Min, Max	36.100, 36.900			36.100, 36.900

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	0.131 ( 0.2658)			0.131 ( 0.2658)
Median	0.100			0.100
Min, Max	-0.100, 0.900			-0.100, 0.900
Week 4				
N	1	12		13
Mean (SD)	36.300 ( )	36.342 ( 0.2193)		36.338 ( 0.2103)
Median	36.300	36.400		36.400
Min, Max	36.300, 36.300	36.000, 36.800		36.000, 36.800
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	0.000 ( )	0.108 ( 0.2999)		0.100 ( 0.2887)
Median	0.000	0.100		0.100
Min, Max	0.000, 0.000	-0.500, 0.600		-0.500, 0.600
Week 6				
N	2	4	7	13
Mean (SD)	36.250 ( 0.2121)	36.225 ( 0.0957)	36.371 ( 0.1113)	36.308 ( 0.1320)
Median	36.250	36.250	36.400	36.300
Min, Max	36.100, 36.400	36.100, 36.300	36.200, 36.500	36.100, 36.500
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	0.100 ( 0.4243)	-0.075 ( 0.2986)	0.143 ( 0.2070)	0.069 ( 0.2626)
Median	0.100	-0.100	0.200	0.000
Min, Max	-0.200, 0.400	-0.400, 0.300	-0.100, 0.400	-0.400, 0.400
Week 8				
N	2	2	9	13
Mean (SD)	36.350 ( 0.2121)	36.700 ( 0.2828)	36.356 ( 0.2404)	36.408 ( 0.2565)
Median	36.350	36.700	36.300	36.400
Min, Max	36.200, 36.500	36.500, 36.900	36.100, 36.900	36.100, 36.900
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	0.200 ( 0.0000)	0.450 ( 0.6364)	0.100 ( 0.3279)	0.169 ( 0.3497)
Median	0.200	0.450	0.100	0.200
Min, Max	0.200, 0.200	0.000, 0.900	-0.200, 0.800	-0.200, 0.900
Week 12				
N	3	2	8	13
Mean (SD)	36.333 ( 0.2082)	36.550 ( 0.4950)	36.238 ( 0.2134)	36.308 ( 0.2597)
Median	36.400	36.550	36.150	36.200
Min, Max	36.100, 36.500	36.200, 36.900	36.000, 36.600	36.000, 36.900
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	0.233 ( 0.1528)	0.300 ( 0.1414)	-0.050 ( 0.2673)	0.069 ( 0.2689)
Median	0.200	0.300	0.000	0.100
Min, Max	0.100, 0.400	0.200, 0.400	-0.400, 0.400	-0.400, 0.400
Week 16				
N	3	3	7	13
Mean (SD)	36.267 ( 0.1155)	36.333 ( 0.2082)	36.357 ( 0.1272)	36.331 ( 0.1377)
Median	36.200	36.400	36.400	36.400
Min, Max	36.200, 36.400	36.100, 36.500	36.200, 36.500	36.100, 36.500
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	0.167 ( 0.0577)	0.100 ( 0.4359)	0.057 ( 0.1718)	0.092 ( 0.2216)
Median	0.200	0.300	0.100	0.100
Min, Max	0.100, 0.200	-0.400, 0.400	-0.200, 0.300	-0.400, 0.400
Week 20				
N	4	3	6	13
Mean (SD)	36.400 ( 0.0816)	36.200 ( 0.1732)	36.300 ( 0.1789)	36.308 ( 0.1605)
Median	36.400	36.100	36.350	36.400
Min, Max	36.300, 36.500	36.100, 36.400	36.000, 36.500	36.000, 36.500
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	0.225 ( 0.1708)	-0.033 ( 0.3215)	0.017 ( 0.3189)	0.069 ( 0.2810)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	0.250	0.100	0.050	0.100
Min, Max	0.000, 0.400	-0.400, 0.200	-0.400, 0.400	-0.400, 0.400
Week 24				
N	4	3	6	13
Mean (SD)	36.350 ( 0.1732)	36.467 ( 0.1155)	36.300 ( 0.0894)	36.354 ( 0.1330)
Median	36.400	36.400	36.300	36.400
Min, Max	36.100, 36.500	36.400, 36.600	36.200, 36.400	36.100, 36.600
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	0.175 ( 0.2872)	0.233 ( 0.2887)	0.017 ( 0.2041)	0.115 ( 0.2478)
Median	0.250	0.400	0.000	0.100
Min, Max	-0.200, 0.400	-0.100, 0.400	-0.200, 0.300	-0.200, 0.400
Week 28				
N	4	3	6	13
Mean (SD)	36.275 ( 0.1500)	36.233 ( 0.1528)	36.300 ( 0.1549)	36.277 ( 0.1423)
Median	36.300	36.200	36.200	36.200
Min, Max	36.100, 36.400	36.100, 36.400	36.200, 36.500	36.100, 36.500
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	0.100 ( 0.0816)	0.000 ( 0.1000)	0.017 ( 0.2229)	0.038 ( 0.1609)
Median	0.100	0.000	0.000	0.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	0.000, 0.200	-0.100, 0.100	-0.200, 0.400	-0.200, 0.400
Week 32				
N	3	3	6	12
Mean (SD)	36.333 ( 0.1155)	36.167 ( 0.1155)	36.267 ( 0.1211)	36.258 ( 0.1240)
Median	36.400	36.100	36.250	36.250
Min, Max	36.200, 36.400	36.100, 36.300	36.100, 36.400	36.100, 36.400
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	0.233 ( 0.2887)	-0.067 ( 0.3512)	-0.017 ( 0.2137)	0.033 ( 0.2708)
Median	0.400	-0.100	0.000	0.000
Min, Max	-0.100, 0.400	-0.400, 0.300	-0.300, 0.300	-0.400, 0.400
Week 36				
N	3	3	6	12
Mean (SD)	36.167 ( 0.0577)	36.333 ( 0.1155)	36.250 ( 0.1643)	36.250 ( 0.1382)
Median	36.200	36.400	36.200	36.200
Min, Max	36.100, 36.200	36.200, 36.400	36.100, 36.500	36.100, 36.500
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	0.067 ( 0.1528)	0.100 ( 0.1732)	-0.033 ( 0.3077)	0.025 ( 0.2379)
Median	0.100	0.200	-0.150	0.000
Min, Max	-0.100, 0.200	-0.100, 0.200	-0.300, 0.400	-0.300, 0.400

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	36.350 ( 0.1915)	36.300 ( 0.1732)	36.250 ( 0.1643)	36.292 ( 0.1656)
Median	36.400	36.200	36.200	36.200
Min, Max	36.100, 36.500	36.200, 36.500	36.100, 36.500	36.100, 36.500
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	0.175 ( 0.2500)	0.067 ( 0.4041)	-0.033 ( 0.1506)	0.054 ( 0.2470)
Median	0.150	0.000	0.000	0.000
Min, Max	-0.100, 0.500	-0.300, 0.500	-0.300, 0.100	-0.300, 0.500
Week 44				
N	4	3	6	13
Mean (SD)	36.275 ( 0.1500)	36.467 ( 0.4041)	36.283 ( 0.1602)	36.323 ( 0.2242)
Median	36.300	36.400	36.200	36.200
Min, Max	36.100, 36.400	36.100, 36.900	36.200, 36.600	36.100, 36.900
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	0.100 ( 0.2582)	0.233 ( 0.5686)	0.000 ( 0.2757)	0.085 ( 0.3338)
Median	0.100	0.400	-0.100	0.000
Min, Max	-0.200, 0.400	-0.400, 0.700	-0.200, 0.500	-0.400, 0.700
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	36.300 ( 0.2449)	36.367 ( 0.2309)	36.350 ( 0.1643)	36.338 ( 0.1895)
Median	36.350	36.500	36.400	36.400
Min, Max	36.000, 36.500	36.100, 36.500	36.100, 36.500	36.000, 36.500
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	0.125 ( 0.2986)	0.133 ( 0.1528)	0.067 ( 0.2251)	0.100 ( 0.2198)
Median	0.100	0.100	0.050	0.100
Min, Max	-0.200, 0.500	0.000, 0.300	-0.300, 0.300	-0.300, 0.500

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Weight (kg)				
Baseline				
N	13			13
Mean (SD)	82.654 ( 12.4756)			82.654 ( 12.4756)
Median	82.000			82.000
Min, Max	61.000, 105.000			61.000, 105.000
Week 1				
N	13			13
Mean (SD)	82.631 ( 12.6591)			82.631 ( 12.6591)
Median	81.000			81.000
Min, Max	60.000, 105.000			60.000, 105.000
Change from Baseline to Week 1				
N	13			13
Mean (SD)	-0.023 ( 1.0663)			-0.023 ( 1.0663)
Median	0.000			0.000
Min, Max	-2.000, 2.000			-2.000, 2.000
Week 2				
N	13			13
Mean (SD)	82.315 ( 12.3657)			82.315 ( 12.3657)
Median	81.000			81.000
Min, Max	59.000, 104.000			59.000, 104.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Change from Baseline to Week 2				
N	13			13
Mean (SD)	-0.338 ( 1.2738)			-0.338 ( 1.2738)
Median	0.000			0.000
Min, Max	-3.000, 1.000			-3.000, 1.000
Week 4				
N	1	12		13
Mean (SD)	94.500 ( )	80.833 ( 12.2165)		81.885 ( 12.2952)
Median	94.500	81.000		81.000
Min, Max	94.500, 94.500	58.000, 104.000		58.000, 104.000
Change from Baseline to Week 4				
N	1	12		13
Mean (SD)	-3.000 ( )	-0.583 ( 1.6765)		-0.769 ( 1.7394)
Median	-3.000	-0.500		-1.000
Min, Max	-3.000, -3.000	-3.000, 1.000		-3.000, 1.000
Week 6				
N	2	4	7	13
Mean (SD)	75.000 ( 25.4558)	84.500 ( 7.7244)	79.643 ( 9.5163)	80.423 ( 11.1801)
Median	75.000	81.000	80.000	80.000
Min, Max	57.000, 93.000	80.000, 96.000	66.000, 95.000	57.000, 96.000
Change from Baseline to Week 6				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	2	4	7	13
Mean (SD)	-4.250 ( 0.3536)	-3.250 ( 4.2720)	-1.071 ( 2.6837)	-2.231 ( 3.1597)
Median	-4.250	-2.000	0.000	-1.000
Min, Max	-4.500, -4.000	-9.000, 0.000	-5.000, 2.000	-9.000, 2.000
Week 8				
N	2	2	9	13
Mean (SD)	75.500 ( 24.7487)	87.000 ( 12.7279)	79.389 ( 7.6149)	79.962 ( 10.7247)
Median	75.500	87.000	81.000	81.000
Min, Max	58.000, 93.000	78.000, 96.000	65.000, 90.000	58.000, 96.000
Change from Baseline to Week 8				
N	2	2	9	13
Mean (SD)	-3.750 ( 1.0607)	-7.500 ( 2.1213)	-1.389 ( 2.6667)	-2.692 ( 3.2438)
Median	-3.750	-7.500	0.000	-3.000
Min, Max	-4.500, -3.000	-9.000, -6.000	-5.000, 1.000	-9.000, 1.000
Week 12				
N	3	2	8	13
Mean (SD)	73.833 ( 16.7506)	87.000 ( 12.7279)	77.950 ( 7.4185)	78.392 ( 10.4901)
Median	74.000	87.000	79.000	78.000
Min, Max	57.000, 90.500	78.000, 96.000	65.000, 89.500	57.000, 96.000
Change from Baseline to Week 12				
N	3	2	8	13

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Mean (SD)	-3.333 ( 4.0415)	-7.500 ( 2.1213)	-3.800 ( 5.4424)	-4.262 ( 4.7414)
Median	-4.000	-7.500	-2.500	-5.000
Min, Max	-7.000, 1.000	-9.000, -6.000	-11.900, 2.500	-11.900, 2.500
Week 16				
N	3	3	7	13
Mean (SD)	72.033 ( 14.1529)	83.467 ( 10.8836)	77.829 ( 6.9178)	77.792 ( 9.6641)
Median	74.000	78.000	78.300	78.000
Min, Max	57.000, 85.100	76.400, 96.000	68.000, 89.000	57.000, 96.000
Change from Baseline to Week 16				
N	3	3	7	13
Mean (SD)	-5.133 ( 6.7715)	-6.200 ( 2.7055)	-4.171 ( 6.4360)	-4.862 ( 5.5061)
Median	-4.000	-6.000	-5.000	-5.000
Min, Max	-12.400, 1.000	-9.000, -3.600	-13.500, 4.000	-13.500, 4.000
Week 20				
N	4	3	6	13
Mean (SD)	73.050 ( 11.7591)	83.800 ( 10.6452)	76.883 ( 8.5511)	77.300 ( 10.0296)
Median	75.000	79.000	79.150	78.300
Min, Max	57.000, 85.200	76.400, 96.000	66.000, 89.000	57.000, 96.000
Change from Baseline to Week 20				
N	4	3	6	13
Mean (SD)	-8.575 ( 8.8538)	-5.867 ( 2.8024)	-2.950 ( 6.4788)	-5.354 ( 6.6940)

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Median	-8.150	-5.000	-1.000	-4.000
Min, Max	-19.000, 1.000	-9.000, -3.600	-12.000, 4.000	-19.000, 4.000
Week 24				
N	4	3	6	13
Mean (SD)	73.050 ( 11.5243)	83.467 ( 10.0724)	76.500 ( 9.3327)	77.046 ( 10.1085)
Median	75.500	79.000	79.000	78.000
Min, Max	57.000, 84.200	76.400, 95.000	62.000, 89.000	57.000, 95.000
Change from Baseline to Week 24				
N	4	3	6	13
Mean (SD)	-8.575 ( 8.6365)	-6.200 ( 3.3645)	-3.333 ( 8.1650)	-5.608 ( 7.3431)
Median	-8.650	-5.000	-1.000	-4.000
Min, Max	-18.000, 1.000	-10.000, -3.600	-16.000, 6.000	-18.000, 6.000
Week 28				
N	4	3	6	13
Mean (SD)	74.625 ( 11.6717)	84.800 ( 8.9286)	78.267 ( 8.3502)	78.654 ( 9.5565)
Median	77.500	81.000	79.750	80.000
Min, Max	58.500, 85.000	78.400, 95.000	68.000, 90.500	58.500, 95.000
Change from Baseline to Week 28				
N	4	3	6	13
Mean (SD)	-7.000 ( 7.3824)	-4.867 ( 4.5004)	-1.567 ( 5.5917)	-4.000 ( 6.0147)
Median	-7.500	-3.000	0.000	-2.500

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Min, Max	-14.000, 1.000	-10.000, -1.600	-8.500, 4.000	-14.000, 4.000
Week 32				
N	3	3	6	12
Mean (SD)	73.000 ( 13.0288)	85.067 ( 8.6495)	78.433 ( 8.4760)	78.733 ( 9.8527)
Median	74.000	81.000	78.250	79.700
Min, Max	59.500, 85.500	79.200, 95.000	68.000, 91.000	59.500, 95.000
Change from Baseline to Week 32				
N	3	3	6	12
Mean (SD)	-4.167 ( 6.8981)	-4.600 ( 4.8042)	-1.400 ( 6.4619)	-2.892 ( 5.8550)
Median	-1.500	-3.000	1.100	-1.150
Min, Max	-12.000, 1.000	-10.000, -0.800	-11.700, 4.000	-12.000, 4.000
Week 36				
N	3	3	6	12
Mean (SD)	73.500 ( 12.8160)	86.033 ( 7.7732)	78.267 ( 8.2604)	79.017 ( 9.6902)
Median	75.000	81.900	78.200	80.100
Min, Max	60.000, 85.500	81.200, 95.000	68.000, 91.000	60.000, 95.000
Change from Baseline to Week 36				
N	3	3	6	12
Mean (SD)	-3.667 ( 7.3711)	-3.633 ( 5.9936)	-1.567 ( 5.9645)	-2.608 ( 5.8107)
Median	-1.000	-2.800	0.000	-1.000
Min, Max	-12.000, 2.000	-10.000, 1.900	-10.600, 4.000	-12.000, 4.000

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Week 40				
N	4	3	6	13
Mean (SD)	76.375 ( 11.9400)	87.833 ( 8.8365)	78.500 ( 8.0843)	80.000 ( 9.8352)
Median	80.000	83.500	78.500	82.000
Min, Max	60.000, 85.500	82.000, 98.000	68.000, 90.200	60.000, 98.000
Change from Baseline to Week 40				
N	4	3	6	13
Mean (SD)	-5.250 ( 6.8007)	-1.833 ( 4.6458)	-1.333 ( 5.9835)	-2.654 ( 5.7762)
Median	-5.500	-0.500	1.000	-0.500
Min, Max	-12.000, 2.000	-7.000, 2.000	-11.000, 4.000	-12.000, 4.000
Week 44				
N	4	3	6	13
Mean (SD)	76.800 ( 10.9557)	87.367 ( 7.5501)	78.867 ( 7.8472)	80.192 ( 9.0966)
Median	80.000	84.100	78.500	82.000
Min, Max	62.000, 85.200	82.000, 96.000	68.000, 90.400	62.000, 96.000
Change from Baseline to Week 44				
N	4	3	6	13
Mean (SD)	-4.825 ( 7.3749)	-2.300 ( 6.5552)	-0.967 ( 5.7375)	-2.462 ( 6.1205)
Median	-4.500	-2.000	1.000	0.000
Min, Max	-12.300, 2.000	-9.000, 4.100	-11.000, 4.000	-12.300, 4.100
Week 48				

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.

Table 14.4.4.1  
Vital Sign Summary  
(Safety Analysis Set)

Parameter (unit) Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
N	4	3	6	13
Mean (SD)	77.650 ( 11.2290)	87.567 ( 7.3935)	78.950 ( 7.8260)	80.538 ( 9.0854)
Median	81.300	84.500	78.750	82.200
Min, Max	62.000, 86.000	82.200, 96.000	68.000, 90.400	62.000, 96.000
Change from Baseline to Week 48				
N	4	3	6	13
Mean (SD)	-3.975 ( 7.6683)	-2.100 ( 6.7550)	-0.883 ( 5.5636)	-2.115 ( 6.0922)
Median	-4.000	-1.800	1.000	0.000
Min, Max	-11.900, 4.000	-9.000, 4.500	-10.500, 4.000	-11.900, 4.500

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.



Table 14.4.4.2  
Summary of QTcF Interval by Dose Level and Visit  
(Safety Analysis Set)

Visit	50 mg/100 mg (N=15)	75 mg/100 mg (N=13)	100 mg/100 mg (N=10)	Overall (N=15)
Baseline				
n	15			15
Mean (SD)	414.56 ( 15.544)			414.56 ( 15.544)
Median	412.74			412.74
Min, Max	391.32, 442.96			391.32, 442.96
Week 1				
n	15			15
Mean (SD)	409.91 ( 15.075)			409.91 ( 15.075)
Median	412.52			412.52
Min, Max	384.81, 432.57			384.81, 432.57
Change from Baseline to Week 1				
n	15			15
Mean (SD)	-4.66 ( 10.552)			-4.66 ( 10.552)
Median	-3.10			-3.10
Min, Max	-33.80, 10.19			-33.80, 10.19

Baseline is the last non-missing value obtained prior to the first dose of study drug.  
Patients are summarized under the dose received at the corresponding visit.  
Patients during the follow-up period, after Week 24, are summarized under the last dose level received.  
Values summarized are the average of three measurements taken at a time point.